NYSE · CIK 0001739174
HLSQ BiomX Inc.
Insider trading from SEC Form 4. Last filing Apr 23, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at BiomX Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 35 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 21, 2025 | James E Flynn director, other | AGrant or award Warrantsderivativeindirect: Through Deerfield Private Design Fund V, L.P. | +1,611,864 | - | - | 1,611,864 | Apr 23, 2025 |
| Apr 21, 2025 | James E Flynn director, other | AGrant or award Warrantsderivativeindirect: Through Deerfield Healthcare Innovations Fund II, L.P. | +1,611,864 | - | - | 1,611,864 | Apr 23, 2025 |
| Apr 14, 2025 | Gregory Louis Merril director | AGrant or award Common Stock Options - right to Buyderivative | +17,600 | $0.00 | $0 | 17,600 | Apr 21, 2025 |
| Apr 14, 2025 | Jonathan Eitan Solomon Chief Executive Officer | AGrant or award Common Stock | +126,748 | $0.00 | $0 | 126,748 | Apr 21, 2025 |
| Apr 14, 2025 | Jesse Goodman director | AGrant or award Common Stock Options - right to Buyderivative | +17,600 | $0.00 | $0 | 17,600 | Apr 21, 2025 |
| Apr 14, 2025 | Eddie Williams director | AGrant or award Common Stock Options - right to Buyderivative | +17,600 | $0.00 | $0 | 17,600 | Apr 21, 2025 |
| Apr 14, 2025 | Alan Charles Moses director | AGrant or award Common Stock Options - right to Buyderivative | +17,600 | $0.00 | $0 | 17,600 | Apr 21, 2025 |
| Apr 14, 2025 | Jonathan S Leff director | AGrant or award Common Stock Options - right to Buyderivative | +17,600 | $0.00 | $0 | 17,600 | Apr 21, 2025 |
| Apr 14, 2025 | Susan Blum director | AGrant or award Common Stock Options - right to Buyderivative | +17,600 | $0.00 | $0 | 17,600 | Apr 21, 2025 |
| Apr 14, 2025 | Russell Greig director | AGrant or award Common Stock Options - right to Buyderivative | +35,200 | $0.00 | $0 | 35,200 | Apr 21, 2025 |
| Apr 14, 2025 | Marina Wolfson Chief Financial Officer | AGrant or award Common Stock | +68,545 | $0.00 | $0 | 68,545 | Apr 21, 2025 |
| Apr 14, 2025 | Merav Bassan Chief Development Officer | AGrant or award Common Stock | +79,597 | $0.00 | $0 | 79,597 | Apr 21, 2025 |
| Apr 14, 2025 | Merav Bassan Chief Development Officer | AGrant or award Common Stock Options - right to Buyderivative | +95,000 | $0.00 | $0 | 95,000 | Apr 21, 2025 |
| Apr 14, 2025 | Jonathan Eitan Solomon Chief Executive Officer | AGrant or award Common Stock Options - right to Buyderivative | +380,500 | $0.00 | $0 | 380,500 | Apr 21, 2025 |
| Apr 14, 2025 | Marina Wolfson Chief Financial Officer | AGrant or award Common Stock Options - right to Buyderivative | +95,000 | $0.00 | $0 | 95,000 | Apr 21, 2025 |
| Apr 14, 2025 | Marina Wolfson Chief Financial Officer | AGrant or award Common Stock | +68,545 | $0.00 | $0 | 68,545 | Apr 18, 2025 |
| Apr 14, 2025 | Merav Bassan Chief Development Officer | AGrant or award Common Stock | +79,597 | $0.00 | $0 | 79,597 | Apr 18, 2025 |
| Apr 14, 2025 | James E Flynn director, other | AGrant or award Stock Option (Right to Buy)derivativeindirect: Through Deerfield Management Company, L.P. | +17,600 | $0.00 | $0 | 17,600 | Apr 18, 2025 |
| Apr 14, 2025 | Susan Blum director | AGrant or award Common Stock Options - right to Buyderivative | -17,600 | $0.00 | $0 | 17,600 | Apr 18, 2025 |
| Apr 14, 2025 | Jonathan Eitan Solomon Chief Executive Officer | AGrant or award Common Stock | +126,748 | $0.00 | $0 | 126,748 | Apr 18, 2025 |
| Apr 14, 2025 | Alan Charles Moses director | AGrant or award Common Stock Options - right to Buyderivative | -17,600 | $0.00 | $0 | 17,600 | Apr 18, 2025 |
| Apr 14, 2025 | Eddie Williams director | AGrant or award Common Stock Options - right to Buyderivative | -17,600 | $0.00 | $0 | 17,600 | Apr 18, 2025 |
| Apr 14, 2025 | Jesse Goodman director | AGrant or award Common Stock Options - right to Buyderivative | -17,600 | $0.00 | $0 | 17,600 | Apr 18, 2025 |
| Apr 14, 2025 | Jonathan S Leff director | AGrant or award Common Stock Options - right to Buyderivative | -17,600 | $0.00 | $0 | 17,600 | Apr 18, 2025 |
| Apr 14, 2025 | Gregory Louis Merril director | AGrant or award Common Stock Options - right to Buyderivative | -17,600 | $0.00 | $0 | 17,600 | Apr 18, 2025 |
| Apr 14, 2025 | Russell Greig director | AGrant or award Common Stock Options - right to Buyderivative | -35,200 | $0.00 | $0 | 35,200 | Apr 18, 2025 |
| Apr 14, 2025 | Jonathan Eitan Solomon Chief Executive Officer | AGrant or award Common Stock Options - right to Buyderivative | -380,500 | $0.00 | $0 | 380,500 | Apr 18, 2025 |
| Apr 14, 2025 | Merav Bassan Chief Development Officer | AGrant or award Common Stock Options - right to Buyderivative | -95,000 | $0.00 | $0 | 95,000 | Apr 18, 2025 |
| Apr 14, 2025 | Marina Wolfson Chief Financial Officer | AGrant or award Common Stock Options - right to Buyderivative | -95,000 | $0.00 | $0 | 95,000 | Apr 18, 2025 |
| Feb 27, 2025 | James E Flynn director, other | MOption exercise Common Stockindirect: Through Deerfield Private Design Fund V, L.P. | +353,249 | $0.93 | $329k | 1,247,054 | Mar 3, 2025 |
| Feb 27, 2025 | James E Flynn director, other | MOption exercise Common Stockindirect: Through Deerfield Healthcare Innovations Fund II, L.P. | +353,249 | $0.93 | $329k | 1,247,054 | Mar 3, 2025 |
| Feb 27, 2025 | James E Flynn director, other | MOption exercise Warrantsderivativeindirect: Through Deerfield Private Design Fund V, L.P. | -1,611,863 | - | - | 405,637 | Mar 3, 2025 |
| Feb 27, 2025 | James E Flynn director, other | MOption exercise Warrantsderivativeindirect: Through Deerfield Healthcare Innovations Fund II, L.P. | -1,611,863 | - | - | 405,637 | Mar 3, 2025 |
| Feb 27, 2025 | James E Flynn director, other | AGrant or award Warrantsderivativeindirect: Through Deerfield Private Design Fund V, L.P. | +1,258,614 | - | - | 1,258,614 | Mar 3, 2025 |
| Feb 27, 2025 | James E Flynn director, other | AGrant or award Warrantsderivativeindirect: Through Deerfield Healthcare Innovations Fund II, L.P. | +1,258,614 | - | - | 1,258,614 | Mar 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Merav BassanChief Development Officer
- Susan Blumcfo, officer, director
- James E Flynnowner, director, other
- Jesse Goodmandirector
- Russell Greigdirector
- Jonathan S Leffdirector
- Gregory Louis Merrildirector
- Alan Charles Mosesdirector
- Jonathan Eitan SolomonChief Executive Officer
- Eddie Williamsdirector
- Marina WolfsonChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.